Supplements

Outlook: India

Vol. 436, No. 7050 pp477-498

India
Top

Editorial

India

Apoorva Mandavilli

doi:10.1038/436477a


Top

Articles

Then and now

Inder Verma celebrates the recent success of India's biotechnology industry, applauds the increased investment and looks to the future.

doi:10.1038/436478a


Biotech boom

India's thriving biotechnology industry is threatened by a change in the law. Will the current high levels of investment be enough to secure its future? K. S. Jayaraman finds out.

doi:10.1038/436480a


Vaccines on trial

One of the largest ever vaccine studies is under way in Kolkata. Paroma Basu uncovers the benefits, and difficulties, of inoculating 60,000 people against cholera and typhoid fever.

doi:10.1038/436484a


India's drug tests

Drug companies are converging on India to conduct low-cost clinical trials. But is it ready to become the outsourcing centre for the world? T. V. Padma investigates.

doi:10.1038/436485a


Ayurveda

Science and business are racing to tap the 3,000-year-old system of medicine for new drugs, says T. V. Padma.

doi:10.1038/436486a


Breathing life into biology

Mriganka Sur says that life sciences will prosper in India once research and teaching reconnect.

doi:10.1038/436487a


Coming home

Reagents may be slow to arrive, but the freedom to explore his own research interests more than compensates. Satyajit Mayor is thriving in India.

doi:10.1038/436488a


Rivalry and red tape

Researchers are suffering as a result of the conflicts between funding agencies. T. V. Padma uncovers plans to heal the rift.

doi:10.1038/436490a


Among the best

India's life-sciences institutes are rewriting the rule books for research. K. S. Jayaraman finds that they are focusing on higher standards and enterprise.

doi:10.1038/436492a


The coming epidemic

A staggering 5.1 million people are estimated to be HIV positive in India. Apoorva Mandavilli finds a country on the brink of a crisis.

doi:10.1038/436496a